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A paramount challenge in carbon–hydrogen (C–H) functional­
ization is to control the site selectivity of the reaction. Current 
methods use directing groups and/or substrate control to pick 
out a particular C–H bond, which limits the breadth of poten­
tial substrates. Recently, an enzymatic strategy to address this 
challenge was reported by Professor Frances H. Arnold and co­
workers Inha Cho (PhD student) and Dr. Zhi­Jun Jia (postdoc­
toral fellow) from the California Institute of Technology (USA). 
The authors used directed evolution to tune the site selecti­
vity of C–H amidation catalyzed by heme enzymes. Professor 
Arnold explained: “Enzymes offer unparalleled selectivity in 
an array of transformations devised first by chemists and now 
established in natural metalloproteins. It’s a splendid oppor­
tunity to merge human chemical ingenuity with the power of 
evolution to make new, synthetically useful catalysts.”
The Arnold group’s study uses an iron­heme cytochrome 
‘P411’ to perform a C–H amidation transformation not found 
in nature. With directed evolution, the researchers fine-tuned 
the site selectivity of intramolecular amidation to deliver 
lactam products of various sizes (Figure 1A). Four different 
en zyme variants, LSsp3, LSsp2, LSβ and LSγ, were evolved from 
a single parent to target specific C–H bonds at selected sites. 
“Notably, the enzymes can override reactivity trends due to 
C–H bond strength, inductive effects, steric accessibility and/
or ring strain to deliver desired lactam products with broad 
substrate scope, excellent regioselectivity and enantioselecti­
vity, and as many as one million total turnovers (TTN),” said 
Professor Arnold. Starting from a parent enzyme with low 
activity, six amino acid mutations in the enzyme’s active site 
boosted the TTN by more than 500-fold for β-lactam syn-
thesis (Figure 1B). This transformation can be performed on 
pre parative scale and some products can be recovered easily 
by filtration from the reaction mixture (Figure 1C). 
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Figure 1 (A) General reaction scheme. (B) Crystal structure of a related variant (PDB ID: 5UCW), with mutated residues marked in 
blue (for LSsp3). (C) Gram-scale synthesis.
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The enzymes use carbonyl nitrenes – previously thought 
ineffective for C–H amidation due to their instability – for this 
reaction. The inspiration for evolving heme proteins to utilize 
carbonyl nitrenes came from earlier work. PhD student Inha 
Cho explained: “Previously we used O­pivaloylhydroxylamine 
as nitrene precursors for hemoprotein­catalyzed aminohy­
droxylation of olefins. The pivaloyl leaving group was high­
ly effective for enhancing the yield and enantioselectivity of 
enzyme­catalyzed nitrene transfer. In 2017, Tsutsumi and 
co­workers (see the original paper for references) reported 
an intramolecular aziridination catalyzed by wild­type cyto­
chrome P450s that use acyl­protected hydroxylamines as na­
tural nitrene precursors in natural product biosynthesis. We 
reasoned that our P411s might accommodate acyl­protected 
hydroxamates to generate nitrene intermediates for C–H 
amid ation.” Upon screening a collection of more than 200 en­
zymes, Cho found an engineered variant of P450BM3 that made 
a small amount of lactam product from a pivaloyl­protected 
hydroxamate precursor. She used this enzyme as a starting 
point for evolution of a ‘lactam synthase’. 
“During mutagenesis and screening, we found some en­
zymes that delivered mixtures of different lactams from the 
same substrate, presumably due to non­optimal control of 
regioselectivity. We believed that these enzymes could be 
engineered to form lactams of specific sizes, exclusively,” ex­
plained Dr. Zhi­Jun Jia. They eventually evolved four lactam 
synthases, LSsp3, LSsp2, LSβ and LSγ, which target different C–H 
bonds in the same substrate. LSsp3 and LSsp2 catalyze C(sp3)–
H amidation and C(sp2)–H amidation, respectively, and en­
able efficient and selective β-lactam and δ-lactam synthesis 
 (Figure 2A). The reactivity and selectivity profiles of LSβ and 
LSγ on substrates with benzylic and homobenzylic C–H bonds 
(Figure 2B) demonstrate the tunability of enzyme­catalyzed 
C–H amidation. Finally, from a substrate with three sets of re­
active C(sp3)–H bonds (Figure 2C), LSβ, LSγ and LSsp3 afforded 
β-, γ- and δ-lactams, respectively. 
The ‘lactam synthases’ were used to prepare a range of 
β-lactams (Figure 3). “Their unique structural features and 
in vivo reactivity make β-lactams versatile chemical building 
blocks as well as medicinal agents with antibacterial activity. 
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Figure 2 (A) Selectivity and scope of LSsp2 and LSsp3-catalyzed intramolecular C–H amidation. (B) Selectivity and scope of LSβ and LSγ. 
(C) Regiodivergent amidation of C(sp3)–H bonds catalyzed by LSβ, LSγ, and LSsp3.
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Since the discovery of penicillin in 1929, extensive use of anti­
biotics has led to the emergence of antibiotic resistance and 
significantly limited future therapeutic options,” explained 
the authors of this study. “To feed new β-lactam antibiotics 
to the pipeline, a general synthetic platform is desirable. We 
hope that this work could provide a modular, sustainable and 
scalable method to efficiently construct diverse libraries of 
chiral β-lactams for drug development. Additionally, the en­
zymes are easy to prepare in E. coli, and the enzymatic reac­
tion is robust.” They concluded: “We hope that chemists will 
be able to use enzymes for synthesis in the same way we use 
small­molecule catalysts today.”
Professor David O’Hagan from St. Andrews University (UK), 
who is an expert on the use of enzymes in organic synthesis, 
commented: “This report in Science is particularly exciting as 
the enzyme is induced to generate nitrenes, intermediates we 
rarely associate with enzymology due to their high reactivity, 
and then various reaction modes are channeled by evolving 
and selecting for different outcomes. Direct methods to form 
C–N bonds have had a major impact in modern organic and 
medicinal chemistry, so engineering this group of biocatalysts 
is particularly impressive and raises the bar. It shows that pro­
tein engineering has the power to harness catalysts for any 
reaction we are prepared to focus on, even those we would not 
normally associate with enzymes.”
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Figure 3 Range of β-lactam products synthesized with this method.
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